Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 5 of 5 entries
Sorted by: Best Match Show Resources per page
Tetramer guided, cell sorter assisted production of clinical grade autologous NY-ESO-1 specific CD8(+) T cells.

Journal for immunotherapy of cancer

Pollack SM, Jones RL, Farrar EA, Lai IP, Lee SM, Cao J, Pillarisetty VG, Hoch BL, Gullett A, Bleakley M, Conrad EU, Eary JF, Shibuya KC, Warren EH, Carstens JN, Heimfeld S, Riddell SR, Yee C.
PMID: 25317334
J Immunother Cancer. 2014 Oct 14;2(1):36. doi: 10.1186/s40425-014-0036-y. eCollection 2014.

BACKGROUND: Adoptive T cell therapy represents an attractive modality for the treatment of patients with cancer. Peripheral blood mononuclear cells have been used as a source of antigen specific T cells but the very low frequency of T cells...

Cite
Pollack SM, Jones RL, Farrar EA, et al. Tetramer guided, cell sorter assisted production of clinical grade autologous NY-ESO-1 specific CD8(+) T cells. J Immunother Cancer. 2014;2(1):36doi: 10.1186/s40425-014-0036-y.
Pollack, S. M., Jones, R. L., Farrar, E. A., Lai, I. P., Lee, S. M., Cao, J., Pillarisetty, V. G., Hoch, B. L., Gullett, A., Bleakley, M., Conrad, E. U., Eary, J. F., Shibuya, K. C., Warren, E. H., Carstens, J. N., Heimfeld, S., Riddell, S. R., & Yee, C. (2014). Tetramer guided, cell sorter assisted production of clinical grade autologous NY-ESO-1 specific CD8(+) T cells. Journal for immunotherapy of cancer, 2(1), 36. https://doi.org/10.1186/s40425-014-0036-y
Pollack, Seth M, et al. "Tetramer guided, cell sorter assisted production of clinical grade autologous NY-ESO-1 specific CD8(+) T cells." Journal for immunotherapy of cancer vol. 2,1 (2014): 36. doi: https://doi.org/10.1186/s40425-014-0036-y
Pollack SM, Jones RL, Farrar EA, Lai IP, Lee SM, Cao J, Pillarisetty VG, Hoch BL, Gullett A, Bleakley M, Conrad EU, Eary JF, Shibuya KC, Warren EH, Carstens JN, Heimfeld S, Riddell SR, Yee C. Tetramer guided, cell sorter assisted production of clinical grade autologous NY-ESO-1 specific CD8(+) T cells. J Immunother Cancer. 2014 Oct 14;2(1):36. doi: 10.1186/s40425-014-0036-y. eCollection 2014. PMID: 25317334; PMCID: PMC4196009.
Copy Download .nbib Format: NLM
Comparative analysis of TCR and CAR signaling informs CAR designs with superior antigen sensitivity and in vivo function.

Science signaling

Salter AI, Rajan A, Kennedy JJ, Ivey RG, Shelby SA, Leung I, Templeton ML, Muhunthan V, Voillet V, Sommermeyer D, Whiteaker JR, Gottardo R, Veatch SL, Paulovich AG, Riddell SR.
PMID: 34429382
Sci Signal. 2021 Aug 24;14(697). doi: 10.1126/scisignal.abe2606.

Chimeric antigen receptor (CAR)-modified T cell therapy is effective in treating lymphomas, leukemias, and multiple myeloma in which the tumor cells express high amounts of target antigen. However, achieving durable remission for these hematological malignancies and extending CAR T...

Cite
Salter AI, Rajan A, Kennedy JJ, et al. Comparative analysis of TCR and CAR signaling informs CAR designs with superior antigen sensitivity and in vivo function. Sci Signal. 2021;14(697)doi: 10.1126/scisignal.abe2606.
Salter, A. I., Rajan, A., Kennedy, J. J., Ivey, R. G., Shelby, S. A., Leung, I., Templeton, M. L., Muhunthan, V., Voillet, V., Sommermeyer, D., Whiteaker, J. R., Gottardo, R., Veatch, S. L., Paulovich, A. G., & Riddell, S. R. (2021). Comparative analysis of TCR and CAR signaling informs CAR designs with superior antigen sensitivity and in vivo function. Science signaling, 14(697), . https://doi.org/10.1126/scisignal.abe2606
Salter, Alexander I, et al. "Comparative analysis of TCR and CAR signaling informs CAR designs with superior antigen sensitivity and in vivo function." Science signaling vol. 14,697 (2021). doi: https://doi.org/10.1126/scisignal.abe2606
Salter AI, Rajan A, Kennedy JJ, Ivey RG, Shelby SA, Leung I, Templeton ML, Muhunthan V, Voillet V, Sommermeyer D, Whiteaker JR, Gottardo R, Veatch SL, Paulovich AG, Riddell SR. Comparative analysis of TCR and CAR signaling informs CAR designs with superior antigen sensitivity and in vivo function. Sci Signal. 2021 Aug 24;14(697). doi: 10.1126/scisignal.abe2606. PMID: 34429382; PMCID: PMC8613804.
Copy Download .nbib Format: NLM
Rationally Designed Transgene-Encoded Cell-Surface Polypeptide Tag for Multiplexed Programming of CAR T-cell Synthetic Outputs.

Cancer immunology research

Johnson AJ, Wei J, Rosser JM, Künkele A, Chang CA, Reid AN, Jensen MC.
PMID: 34244298
Cancer Immunol Res. 2021 Sep;9(9):1047-1060. doi: 10.1158/2326-6066.CIR-20-0470. Epub 2021 Jul 09.

Synthetic immunology, as exemplified by chimeric antigen receptor (CAR) T-cell immunotherapy, has transformed the treatment of relapsed/refractory B cell-lineage malignancies. However, there are substantial barriers-including limited tumor homing, lack of retention of function within a suppressive tumor microenvironment, and...

Cite
Johnson AJ, Wei J, Rosser JM, et al. Rationally Designed Transgene-Encoded Cell-Surface Polypeptide Tag for Multiplexed Programming of CAR T-cell Synthetic Outputs. Cancer Immunol Res. 2021;9(9):1047-1060doi: 10.1158/2326-6066.CIR-20-0470.
Johnson, A. J., Wei, J., Rosser, J. M., Künkele, A., Chang, C. A., Reid, A. N., & Jensen, M. C. (2021). Rationally Designed Transgene-Encoded Cell-Surface Polypeptide Tag for Multiplexed Programming of CAR T-cell Synthetic Outputs. Cancer immunology research, 9(9), 1047-1060. https://doi.org/10.1158/2326-6066.CIR-20-0470
Johnson, Adam J, et al. "Rationally Designed Transgene-Encoded Cell-Surface Polypeptide Tag for Multiplexed Programming of CAR T-cell Synthetic Outputs." Cancer immunology research vol. 9,9 (2021): 1047-1060. doi: https://doi.org/10.1158/2326-6066.CIR-20-0470
Johnson AJ, Wei J, Rosser JM, Künkele A, Chang CA, Reid AN, Jensen MC. Rationally Designed Transgene-Encoded Cell-Surface Polypeptide Tag for Multiplexed Programming of CAR T-cell Synthetic Outputs. Cancer Immunol Res. 2021 Sep;9(9):1047-1060. doi: 10.1158/2326-6066.CIR-20-0470. Epub 2021 Jul 09. PMID: 34244298; PMCID: PMC8415133.
Copy Download .nbib Format: NLM
Rationally Designed Transgene-Encoded Cell-Surface Polypeptide Tag for Multiplexed Programming of CAR T-cell Synthetic Outputs.

Cancer immunology research

Johnson AJ, Wei J, Rosser JM, Künkele A, Chang CA, Reid AN, Jensen MC.
PMID: 34244298
Cancer Immunol Res. 2021 Sep;9(9):1047-1060. doi: 10.1158/2326-6066.CIR-20-0470. Epub 2021 Jul 09.

Synthetic immunology, as exemplified by chimeric antigen receptor (CAR) T-cell immunotherapy, has transformed the treatment of relapsed/refractory B cell-lineage malignancies. However, there are substantial barriers-including limited tumor homing, lack of retention of function within a suppressive tumor microenvironment, and...

Cite
Johnson AJ, Wei J, Rosser JM, et al. Rationally Designed Transgene-Encoded Cell-Surface Polypeptide Tag for Multiplexed Programming of CAR T-cell Synthetic Outputs. Cancer Immunol Res. 2021;9(9):1047-1060doi: 10.1158/2326-6066.CIR-20-0470.
Johnson, A. J., Wei, J., Rosser, J. M., Künkele, A., Chang, C. A., Reid, A. N., & Jensen, M. C. (2021). Rationally Designed Transgene-Encoded Cell-Surface Polypeptide Tag for Multiplexed Programming of CAR T-cell Synthetic Outputs. Cancer immunology research, 9(9), 1047-1060. https://doi.org/10.1158/2326-6066.CIR-20-0470
Johnson, Adam J, et al. "Rationally Designed Transgene-Encoded Cell-Surface Polypeptide Tag for Multiplexed Programming of CAR T-cell Synthetic Outputs." Cancer immunology research vol. 9,9 (2021): 1047-1060. doi: https://doi.org/10.1158/2326-6066.CIR-20-0470
Johnson AJ, Wei J, Rosser JM, Künkele A, Chang CA, Reid AN, Jensen MC. Rationally Designed Transgene-Encoded Cell-Surface Polypeptide Tag for Multiplexed Programming of CAR T-cell Synthetic Outputs. Cancer Immunol Res. 2021 Sep;9(9):1047-1060. doi: 10.1158/2326-6066.CIR-20-0470. Epub 2021 Jul 09. PMID: 34244298; PMCID: PMC8415133.
Copy Download .nbib Format: NLM
Comparative analysis of TCR and CAR signaling informs CAR designs with superior antigen sensitivity and in vivo function.

Science signaling

Salter AI, Rajan A, Kennedy JJ, Ivey RG, Shelby SA, Leung I, Templeton ML, Muhunthan V, Voillet V, Sommermeyer D, Whiteaker JR, Gottardo R, Veatch SL, Paulovich AG, Riddell SR.
PMID: 34429382
Sci Signal. 2021 Aug 24;14(697). doi: 10.1126/scisignal.abe2606.

Chimeric antigen receptor (CAR)-modified T cell therapy is effective in treating lymphomas, leukemias, and multiple myeloma in which the tumor cells express high amounts of target antigen. However, achieving durable remission for these hematological malignancies and extending CAR T...

Cite
Salter AI, Rajan A, Kennedy JJ, et al. Comparative analysis of TCR and CAR signaling informs CAR designs with superior antigen sensitivity and in vivo function. Sci Signal. 2021;14(697)doi: 10.1126/scisignal.abe2606.
Salter, A. I., Rajan, A., Kennedy, J. J., Ivey, R. G., Shelby, S. A., Leung, I., Templeton, M. L., Muhunthan, V., Voillet, V., Sommermeyer, D., Whiteaker, J. R., Gottardo, R., Veatch, S. L., Paulovich, A. G., & Riddell, S. R. (2021). Comparative analysis of TCR and CAR signaling informs CAR designs with superior antigen sensitivity and in vivo function. Science signaling, 14(697), . https://doi.org/10.1126/scisignal.abe2606
Salter, Alexander I, et al. "Comparative analysis of TCR and CAR signaling informs CAR designs with superior antigen sensitivity and in vivo function." Science signaling vol. 14,697 (2021). doi: https://doi.org/10.1126/scisignal.abe2606
Salter AI, Rajan A, Kennedy JJ, Ivey RG, Shelby SA, Leung I, Templeton ML, Muhunthan V, Voillet V, Sommermeyer D, Whiteaker JR, Gottardo R, Veatch SL, Paulovich AG, Riddell SR. Comparative analysis of TCR and CAR signaling informs CAR designs with superior antigen sensitivity and in vivo function. Sci Signal. 2021 Aug 24;14(697). doi: 10.1126/scisignal.abe2606. PMID: 34429382; PMCID: PMC8613804.
Copy Download .nbib Format: NLM
Showing 1 to 5 of 5 entries